Schizoaffective Disorders Completed Phase 3 Trials for Paliperidone (DB01267)

Also known as: Schizoaffective disorder / Schizophrenia schizoaffective / Schizoaffective psychosis / Schizo-affective type schizophrenia

IndicationStatusPhase
DBCOND0033299 (Schizoaffective Disorders)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00397033Evaluation of Effectiveness and Safety of Paliperidone Extended Release in Patients With Schizoaffective Disorder.Treatment
NCT00412373Evaluation of Effectiveness and Safety of Flexible-dose Paliperidone Extended Release in Patients With Schizoaffective Disorder.Treatment
NCT01193153A Study to Evaluate the Efficacy of Paliperidone Palmitate in the Prevention of Relapse of the Symptoms of Schizoaffective DisorderPrevention